In vitro biological evaluation of glyburide as potential inhibitor of collagenases

Bodiga, Vijaya Lakshmi; Eda, Sasidhar Reddy; Chavali, Sai Shashank; Revur, Nagasaisreelekha Nagavalli; Zhang, Anita; Thokala, Sandhya; Bodiga, Sreedhar

doi:10.1016/j.ijbiomac.2014.06.054

Cited by 8 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glibenclamide was shown to decrease the secretion and mRNA expression of pro-inflammatory cytokines such as IL-1β and IL-18 that are predominantly produced by macrophages in the wounded region [27]. Additionally, it was shown to be a potential inhibitor of collagenases, offering additional advantages in controlling MMP activation and collagen degradation [28]. Improvement in the healing cascade was reported upon the combination of these repurposed antidiabetic drugs with natural bioactive polymers for their pivotal role in healing.…”

Section: Introductionmentioning

confidence: 99%

Glibenclamide Nanocrystal-Loaded Bioactive Polymeric Scaffolds for Skin Regeneration: In Vitro Characterization and Preclinical Evaluation

et al. 2021

View full text Add to dashboard Cite

Skin restoration following full-thickness injury poses significant clinical challenges including inflammation and scarring. Medicated scaffolds formulated from natural bioactive polymers present an attractive platform for promoting wound healing. Glibenclamide was formulated in collagen/chitosan composite scaffolds to fulfill this aim. Glibenclamide was forged into nanocrystals with optimized colloidal properties (particle size of 352.2 nm, and polydispersity index of 0.29) using Kolliphor as a stabilizer to allow loading into the hydrophilic polymeric matrix. Scaffolds were prepared by the freeze drying method using different total polymer contents (3–6%) and collagen/chitosan ratios (0.25–2). A total polymer content of 3% at a collagen/chitosan ratio of 2:1 (SCGL3-2) was selected based on the results of in vitro characterization including the swelling index (1095.21), porosity (94.08%), mechanical strength, rate of degradation and in vitro drug release. SCGL3-2 was shown to be hemocompatible based on the results of protein binding, blood clotting and percentage hemolysis assays. In vitro cell culture studies on HSF cells demonstrated the biocompatibility of nanocrystals and SCGL3-2. In vivo studies on a rat model of a full-thickness wound presented rapid closure with enhanced histological and immunohistochemical parameters, revealing the success of the scaffold in reducing inflammation and promoting wound healing without scar formation. Hence, SCGL3-2 could be considered a potential dermal substitute for skin regeneration.

show abstract

Section: Introductionmentioning

confidence: 99%

Glibenclamide Nanocrystal-Loaded Bioactive Polymeric Scaffolds for Skin Regeneration: In Vitro Characterization and Preclinical Evaluation

et al. 2021

View full text Add to dashboard Cite

show abstract

“…ACE inhibitors have an inhibitory effect on collagen biosynthesis [5] as well, which can lead to a delay in wound healing. Studies on calcium channel blockers show that they improve the tensile strength, but not the epithelialization of the skin [6][7][8], accordingly their effect on wound healing cannot be evaluated exactly. β-blockers have a systemic and locally accelerating effect on wound healing [9,10].…”

Section: Resultsmentioning

confidence: 99%

Side Effects of Frequently Used Oral Antidiabetics and Antihypertensive Drugs on Wound Healing in vitro

Stuermer

2019

Ann Biomed Res

View full text Add to dashboard Cite

“… 60 , 69 Furthermore, glyburide has been documented to have direct inhibitory effects on many metalloproteinases, including MMP-13. 70 Therefore, the retinal protective effects of glyburide in DR might be a combination of inhibition of SUR1 and MMP-13, which will require further exploration.…”

Section: Discussionmentioning

confidence: 99%

Probable Treatment Targets for Diabetic Retinopathy Based on an Integrated Proteomic and Genomic Analysis

Valdivia

Ren

et al. 2023

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose Using previously approved medications for new indications can expedite the lengthy and expensive drug development process. We describe a bioinformatics pipeline that integrates genomics and proteomics platforms to identify already-approved drugs that might be useful to treat diabetic retinopathy (DR). Methods Proteomics analysis of vitreous humor samples from 12 patients undergoing pars plana vitrectomy for DR and a whole genome dataset (UKBiobank TOPMed-imputed) from 1330 individuals with DR and 395,155 controls were analyzed independently to identify biological pathways associated with DR. Common biological pathways shared between both datasets were further analyzed (STRING and REACTOME analyses) to identify target proteins for probable drug modulation. Curated target proteins were subsequently analyzed by the BindingDB database to identify chemical compounds they interact with. Identified chemical compounds were further curated through the Expasy SwissSimilarity database for already-approved drugs that interact with target proteins. Results The pathways in each dataset (proteomics and genomics) converged in the upregulation of a previously unknown pathway involved in DR (RUNX2 signaling; constituents MMP-13 and LGALS3), with an emphasis on its role in angiogenesis and blood–retina barrier. Bioinformatics analysis identified U.S. Food and Drug Administration (FDA)-approved medications (raltitrexed, pemetrexed, glyburide, probenecid, clindamycin hydrochloride, and ticagrelor) that, in theory, may modulate this pathway. Conclusions The bioinformatics pipeline described here identifies FDA-approved drugs that can be used for new alternative indications. These theoretical candidate drugs should be validated with experimental studies. Translational Relevance Our study suggests possible drugs for DR treatment based on an integrated proteomics and genomics pipeline. This approach can potentially expedite the drug discovery process by identifying already-approved drugs that might be used for new indications.

show abstract

In vitro biological evaluation of glyburide as potential inhibitor of collagenases

Cited by 8 publications

References 21 publications

Glibenclamide Nanocrystal-Loaded Bioactive Polymeric Scaffolds for Skin Regeneration: In Vitro Characterization and Preclinical Evaluation

Glibenclamide Nanocrystal-Loaded Bioactive Polymeric Scaffolds for Skin Regeneration: In Vitro Characterization and Preclinical Evaluation

Side Effects of Frequently Used Oral Antidiabetics and Antihypertensive Drugs on Wound Healing in vitro

Probable Treatment Targets for Diabetic Retinopathy Based on an Integrated Proteomic and Genomic Analysis

Contact Info

Product

Resources

About